510(k)

K162564: Medisign GH81 Blood Glucose Monitoring System, Medisign GH82 Blood Glucose Monitoring System, Medisign GH83 Blood Glucose Monitoring System, Medisign GH81 BT Blood Glucose Monitoring System, Medisign GH82 BT Blood Glucose Monitoring System, Medisign GH83 BT Blood Glucose Monitoring System

FDA 510(k) · Tianjin Empecs Medical Device Co., Ltd. · decided Jun 7, 2017

Key facts

510(k) number K162564
Device name Medisign GH81 Blood Glucose Monitoring System, Medisign GH82 Blood Glucose Monitoring System, Medisign GH83 Blood Glucose Monitoring System, Medisign GH81 BT Blood Glucose Monitoring System, Medisign GH82 BT Blood Glucose Monitoring System, Medisign GH83 BT Blood Glucose Monitoring System
Applicant Tianjin Empecs Medical Device Co., Ltd.
Product code NBW
Subsequent product codes LFR
Date received Sep 14, 2016
Decision date Jun 7, 2017
Decision Substantially equivalent (SESE)
Submission type Traditional
Review panel Clinical Chemistry
Medical specialty Clinical Chemistry

At a glance

  • None MAUDE adverse event reports
  • None Recall events
  • 1–9 UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • None Later submissions citing this device
  • 100–999 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications